Cheuk Hong Leung
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (5)
Table S1. Patient and tumor characteristics. Table S2. Representativeness of study participants. Table S3. Clinical and histopathologic characteristics of individual patients. Table S4. Treatment related adverse events that occurred after first dose. Table S5. Adverse events related to immune checkpoint blockade. Table S6. Serious adverse events.
Year:
2025
In a phase II trial, patients with local-regionally advanced human papillomavirus–positive oropharyngeal carcinoma ( n = 35) received ipilimumab (anti-CTLA4) and nivolumab (anti–PD-1) as induction immunotherapy and concurrently with radiotherapy (NCT03799445). Coprimary endpoints included 6-month complete metabolic response rate (94%) and 2-year progression-free survival (84%). Induction yielded a 46% major histopathologic response rate. Single-cell profiling revealed responders had higher baseline intratumoral CD8 + T cells with a tumor-reactive, tissue-resident memory (TRM) phenotype and a treatment-related decrease in effector regulatory T (eTreg) cells. The eTreg decrease correlated with CD8 + T-cell clonotype transitioning from TRM to effector memory and IFNG + effector cells. In nonresponders, clonotypes transitioned to exhausted TRM and proliferating cells. Multivariable regression modeling determined that the baseline feature most associated with reduction in tumor viability was the proportion of FCGR3A -expressing NK cells, which are capable of ipilimumab-dependent depletion of CTLA4 high eTregs. eTreg depletion may be critical for major response to induction dual immune checkpoint blockade (ICB). Significance: The relative contributions of CD28 costimulation restoration versus Treg depletion to clinical response to CTLA4 ICB is a matter of considerable controversy. In this study, we provide compelling data that eTreg depletion is critical to tumor clearance in patients treated with dual PD-1 and CTLA4 ICB.
Year:
2025
Fig. S1. Patient disposition and characteristics. Fig. S2. Timing of OI biopsy collection did not correlate with response. Fig. S3. Major cell types identified in the tumor immune microenvironment. Fig. S4. CD4+ T cells identified in the tumor immune microenvironment. Fig. S5. Effector Treg cells in the HPV-positive OPC TIME highly express activation markers. Fig. S6. Treatment-induced changes in Treg proportions and clonotype frequencies. Fig. S7. CD8+ T cells in MHRs have different transcriptional programs vs those in nMHRs. Fig. S8. CD8+ T cells identified in the tumor immune microenvironment. Fig. S9. T cell clusters did not vary by anatomic site. Fig. S10. TRM CD8+ T cells had high expression of tumor-reactive, cytotoxic and checkpoint genes. Fig. S11. Fluorescent imaging of antigen-experienced, memory CD8+ T cells in baseline tumors. Fig. S12. Clonality of CD4+ T-cell TCR repertoire. Fig. S13. CD8+ T-cell TCR repertoire clonality and dynamics. Fig. S14. Phenotypes of treatment-altered CD8 clonotypes varied by response. Fig. S15. Predominant phenotypes of treatment-responsive CD8+ T-cell clonotypes. Fig. S16. Identification of HPV-specific TCRs. Fig. S17. NK cells that express Fc gamma receptor IIIa (CD16) are more activated than those that do not. Fig. S18. Increase in proportion of Effector1(IFNG+) cells associated with reduction in tumor viability.
Year:
2025
Accumulating evidence indicates that the gut microbiome influences cancer progression and therapy. We recently showed that progressive changes in gut microbial diversity and composition are closely coupled with tobacco-associated lung adenocarcinoma in a human-relevant mouse model. Furthermore, we demonstrated that the loss of the antimicrobial protein Lcn2 in these mice exacerbates protumor inflammatory phenotypes while further reducing microbial diversity. Yet, how gut microbiome alterations impinge on lung adenocarcinoma development remains poorly understood. In this study, we investigated the role of gut microbiome changes in lung adenocarcinoma development using fecal microbiota transfer and delineated a pathway by which gut microbiome alterations incurred by loss of Lcn2 fostered the proliferation of proinflammatory bacteria of the genus Alistipes , triggering gut inflammation. This inflammation propagated systemically, exerting immunosuppression within the tumor microenvironment, augmenting tumor growth through an IL6-dependent mechanism and dampening response to immunotherapy. Corroborating our preclinical findings, we found that patients with lung adenocarcinoma with a higher relative abundance of Alistipes species in the gut showed diminished response to neoadjuvant immunotherapy. These insights reveal the role of microbiome-induced inflammation in lung adenocarcinoma and present new potential targets for interception and therapy.
Year:
2024
Cancer cells with BRCA1/2 deficiencies are sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. We evaluated the efficacy of talazoparib in DNA-Damage Repair (DDR)-altered patients. In this phase II trial, patients were enrolled onto one of four cohorts based on molecular alterations: (1) somatic BRCA 1/2, (2) other homologous recombination repair pathway, (3) PTEN and (4) germline BRCA1/2 . The primary endpoint was a clinical benefit rate (CBR): complete response, partial response or stable disease ≥24 weeks. 79 patients with a median of 4 lines of therapy were enrolled. CBR for cohorts 1–4 were: 32.5%, 19.7%, 9.4% and 30.6%, respectively. PTEN mutations correlated with reduced survival and a trend towards shorter time to progression.Talazoparib demonstrated clinical benefit in selected DDR-altered patients. PTEN mutations/loss patients derived limited clinical benefit. Further study is needed to determine whether PTEN is prognostic or predictive of response to PARP inhibitors.
Year:
2024
Collaborators (41)
Neil Gross
Professor
The University of Texas MD Anderson Cancer Center
Kanwal Raghav
Professor
The University of Texas MD Anderson Cancer Center
Gordon Mills
Professor
Oregon Health & Science University
Jay Paul Reddy
Assistant Professor
The University of Texas MD Anderson Cancer Center
matthew ross
Assistant Professor
Baylor College of Medicine
Michael A. Curran
Professor
The University of Texas MD Anderson Cancer Center
Michelle D. Williams
The University of Texas MD Anderson Cancer Center
Kristi Hoffman
Assistant Professor
Baylor College of Medicine
Aung Naing
The University of Texas MD Anderson Cancer Center
Baohua Sun
The University of Texas MD Anderson Cancer Center
Vivek Subbiah
Professor of Medicine and of Pediatrics
Stanford University
Apostolia M. Tsimberidou
Professor
The University of Texas MD Anderson Cancer Center
Joe Dan Dunn
The University of Texas MD Anderson Cancer Center
Edwin Roger Parra
Associate Professor
The University of Texas MD Anderson Cancer Center
Akagi Keiko
The University of Texas MD Anderson Cancer Center
Jack Phan
Physician/Associate Professor
MD Anderson Cancer Center
Junya Fujimoto
Professor and Chair
Hiroshima University Hospital
Renata Ferrarotto
The University of Texas MD Anderson Cancer Center
Sarina Piha-Paul
Professor
The University of Texas MD Anderson Cancer Center
J. Jack Lee
Professor
The University of Texas MD Anderson Cancer Center
Miriam Lango
Professor
The University of Texas MD Anderson Cancer Center
Jennifer A. Wargo
The University of Texas MD Anderson Cancer Center
Maura L. Gillison
The University of Texas MD Anderson Cancer Center
Qingnan Liang
Assistant Professor
University of Oklahoma Health Sciences Center
Robert Jenq
Professor
City Of Hope National Medical Center
Jason Johnson
Section Chief, Neuroradiology / Associate Professor
Yale University
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Nils Rudqvist
Assistant Professor (joint appointment)
The University of Texas MD Anderson Cancer Center
Seyed Javad Moghaddam
Professor
The University of Texas MD Anderson Cancer Center
Shan He
The University of Texas MD Anderson Cancer Center
Meng Li
Assistant Professor
Rice University
Shengbin Ye
Assistant Professor of Instruction
Northwestern University
Suyu Liu
Associate Professor
The University of Texas MD Anderson Cancer Center
Nadim Ajami
Executive Director
The University of Texas MD Anderson Cancer Center
Ken Chen
Professor
The University of Texas MD Anderson Cancer Center
Don L. Gibbons
The University of Texas MD Anderson Cancer Center
Humam Kadara
The University of Texas MD Anderson Cancer Center
Joseph Petrosino
Department Chair
Baylor College of Medicine
Jaffer A. Ajani
Professor
The University of Texas MD Anderson Cancer Center
Linghua Wang
Executive Director & Head
The University of Texas MD Anderson Cancer Center
Clifton D Fuller
Professor (Tenured)
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.